Terminal · Institutions
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Every 13F-reported equity position this quarter, with its quarter-over-quarter change — each row traces back to the SEC filing.
Aisling Capital LLC (CIK 1571076) reported $45.3M across 5 reported positions in its SEC 13F filing for 2019-09-30. Largest positions: AIMT ($26.0M, 57.34%), ADMA ($16.1M, 35.46%), CDTX ($1.8M, 3.93%), ASXC ($1.5M, 3.27%), VRAY ($0, 0.00%). Source: SEC Form 13F.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | AIMT | AIMMUNE THERAPEUTICS INC. | $26.0M | 57.34% | 1.2M | Trimmed |
| 2 | ADMA | ADMA BIOLOGICS INC | $16.1M | 35.46% | 3.6M | Hold |
| 3 | CDTX | CIDARA THERAPEUTICS INC. | $1.8M | 3.93% | 891,614 | Trimmed |
| 4 | ASXC | TRANSENTERIX INC. | $1.5M | 3.27% | 2.4M | Hold |
| 5 | VRAY | VIEWRAY INC. | $0 | 0.00% | 18,964 | New |
Source: SEC Form 13F filings · as of 2019-09-30